AR084863A1 - Inhibidores de girasa y topoisomerasa iv utiles para tratar infecciones bacterianas y composiciones farmaceuticas que los contienen - Google Patents

Inhibidores de girasa y topoisomerasa iv utiles para tratar infecciones bacterianas y composiciones farmaceuticas que los contienen

Info

Publication number
AR084863A1
AR084863A1 ARP120100137A ARP120100137A AR084863A1 AR 084863 A1 AR084863 A1 AR 084863A1 AR P120100137 A ARP120100137 A AR P120100137A AR P120100137 A ARP120100137 A AR P120100137A AR 084863 A1 AR084863 A1 AR 084863A1
Authority
AR
Argentina
Prior art keywords
girasa
topoisomerase
inhibitors
useful
pharmaceutical compositions
Prior art date
Application number
ARP120100137A
Other languages
English (en)
Inventor
Emanuele Perola
Tiran Arnaud Le
Anne GRILLOT
Paul Laure-Charifson
Youssef L Bennani
Hardwin Odowd
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR084863A1 publication Critical patent/AR084863A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula caracterizado porque tiene la fórmula (1) donde R es hidrógeno o flúor; X es hidrógeno, -PO(OH)2, -PO(OH)O-M+, -PO(O-)2·2M+, o -PO(O-)2·D2+; M+ es un catión monovalente farmacéuticamente aceptable; y D2+ es un catión divalente farmacéuticamente aceptable; o una sal farmacéuticamente aceptable del mismo.
ARP120100137A 2011-01-14 2012-01-16 Inhibidores de girasa y topoisomerasa iv utiles para tratar infecciones bacterianas y composiciones farmaceuticas que los contienen AR084863A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161432965P 2011-01-14 2011-01-14
US201161499134P 2011-06-20 2011-06-20
US201161515249P 2011-08-04 2011-08-04
US201161515174P 2011-08-04 2011-08-04

Publications (1)

Publication Number Publication Date
AR084863A1 true AR084863A1 (es) 2013-07-10

Family

ID=45567120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100137A AR084863A1 (es) 2011-01-14 2012-01-16 Inhibidores de girasa y topoisomerasa iv utiles para tratar infecciones bacterianas y composiciones farmaceuticas que los contienen

Country Status (18)

Country Link
US (2) US8481551B2 (es)
EP (1) EP2663557B1 (es)
JP (1) JP6085829B2 (es)
KR (1) KR101897952B1 (es)
CN (1) CN103443096B (es)
AR (1) AR084863A1 (es)
AU (1) AU2012205415B2 (es)
BR (1) BR112013017974B1 (es)
CA (1) CA2824516C (es)
CL (1) CL2013002025A1 (es)
ES (1) ES2545516T3 (es)
IL (1) IL227406A (es)
MX (1) MX339455B (es)
RU (1) RU2609259C2 (es)
SG (1) SG191946A1 (es)
TW (1) TWI546298B (es)
WO (1) WO2012097269A1 (es)
ZA (1) ZA201305233B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103443096B (zh) * 2011-01-14 2016-06-29 沃泰克斯药物股份有限公司 促旋酶和拓扑异构酶iv抑制剂
SG191924A1 (en) * 2011-01-14 2013-08-30 Vertex Pharma Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
TWI535714B (zh) * 2011-01-14 2016-06-01 維泰克斯製藥公司 旋轉酶抑制劑（ｒ）－１－乙基－３－［６－氟－５－［２－（１－羥基－１－甲基－乙基）嘧啶－５－基］－７－（四氫呋喃－２－基）－１ｈ－苯并咪唑－２－基］脲之固體形式
JP6006235B2 (ja) * 2011-01-14 2016-10-12 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ジャイレースおよびトポイソメラーゼｉｖ阻害剤を作製するプロセス
EP2721026B1 (en) * 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
TWI595002B (zh) * 2012-07-18 2017-08-11 思沛羅三南公司 （Ｒ）－２－（５－（２－（３－乙基脲基）－６－氟－７－（四氫呋喃－２－基）－１Ｈ－苯并［ｄ］咪唑－５－基）嘧啶－２－基）丙烷－２－基磷酸二氫鹽之固體形式及其鹽
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
CA2938459A1 (en) 2014-02-03 2015-08-06 Spero Gyrase, Inc. Antibacterial compounds
JP7016853B2 (ja) * 2016-07-07 2022-02-07 サイクレリオン・セラピューティクス，インコーポレーテッド ｓＧＣ刺激剤のリンプロドラッグ
JPWO2018174288A1 (ja) 2017-03-24 2020-01-23 大正製薬株式会社 ２（１ｈ）−キノリノン誘導体
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
CN109464472B (zh) * 2019-01-17 2023-09-15 广西医科大学 一种铜绿假单胞菌家兔脓胸引流管生物膜模型建立方法
CN109464471B (zh) * 2019-01-17 2023-09-19 广西医科大学 一种铜绿假单胞菌家兔脓胸脓絮状物生物膜模型建立方法
KR20240090712A (ko) * 2021-10-26 2024-06-21 스페로 테라퓨틱스, 인코퍼레이티드 Spr720의 인간 유효 용량 및 투여 스케줄
WO2024112738A1 (en) * 2022-11-22 2024-05-30 University Of Maryland, Baltimore Bovine colostrum-derived nutritional supplements and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015676A1 (de) 1970-04-02 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel
US4174400A (en) 1978-09-13 1979-11-13 Merck & Co., Inc. Anthelmintic benzimidazoles
US4512998A (en) 1980-10-20 1985-04-23 Schering Corporation Anthelmintic benzimidazole carbamates
CA2028530A1 (en) 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
JPH09502987A (ja) 1993-09-22 1997-03-25 ゾーマ コーポレイション 殺菌性／浸透性が向上した（ｂｐｉ）タンパク質生成物および抗生物質の投与によるグラム陰性細菌感染の治療方法
PT754050E (pt) 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
GB9911594D0 (en) 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US7419678B2 (en) 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
ES2331250T3 (es) 2000-12-15 2009-12-28 Vertex Pharmaceuticals Incorporated Inhibidores de la girasa bacteriana y usos de los mismos.
US20030229390A1 (en) 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
JP2006519623A (ja) 2001-10-25 2006-08-31 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション タンパクチロシンキナーゼインヒビターで被覆されたまたは含浸された血管ステントまたは血管グラフト、およびその使用方法
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
ATE345132T1 (de) 2002-06-13 2006-12-15 Vertex Pharma 2-ureido-6-heteroaryl-3h-benzoimidazol-4- carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
CN101538263A (zh) * 2002-06-13 2009-09-23 沃泰克斯药物股份有限公司 作为促旋酶和/或拓扑异构酶iv的抑制剂用于治疗细菌感染的2－脲基－6－杂芳基－3h－苯并咪唑－4－羧酸衍生物和相关化合物
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
EP1861393A2 (en) * 2005-03-04 2007-12-05 AstraZeneca AB Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
US8394803B2 (en) * 2005-11-07 2013-03-12 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
EP2102199B1 (en) 2006-12-04 2011-04-27 AstraZeneca AB Antibacterial polycyclic urea compounds
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
US20110166088A1 (en) 2008-06-25 2011-07-07 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
CN102725274A (zh) 2009-10-16 2012-10-10 Rib-X制药公司 抗微生物化合物和其制备和使用方法
AU2011313820A1 (en) 2010-10-08 2013-04-11 Biota Europe Ltd Antibacterial compounds
JP6006235B2 (ja) * 2011-01-14 2016-10-12 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ジャイレースおよびトポイソメラーゼｉｖ阻害剤を作製するプロセス
TWI535714B (zh) 2011-01-14 2016-06-01 維泰克斯製藥公司 旋轉酶抑制劑（ｒ）－１－乙基－３－［６－氟－５－［２－（１－羥基－１－甲基－乙基）嘧啶－５－基］－７－（四氫呋喃－２－基）－１ｈ－苯并咪唑－２－基］脲之固體形式
CN103443096B (zh) 2011-01-14 2016-06-29 沃泰克斯药物股份有限公司 促旋酶和拓扑异构酶iv抑制剂
SG191924A1 (en) * 2011-01-14 2013-08-30 Vertex Pharma Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
EP2721026B1 (en) * 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
US8906902B2 (en) 2012-03-22 2014-12-09 Biota Europe Limited Antibacterial compounds
TWI595002B (zh) * 2012-07-18 2017-08-11 思沛羅三南公司 （Ｒ）－２－（５－（２－（３－乙基脲基）－６－氟－７－（四氫呋喃－２－基）－１Ｈ－苯并［ｄ］咪唑－５－基）嘧啶－２－基）丙烷－２－基磷酸二氫鹽之固體形式及其鹽
US9572809B2 (en) * 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases

Also Published As

Publication number Publication date
WO2012097269A1 (en) 2012-07-19
ES2545516T3 (es) 2015-09-11
CN103443096B (zh) 2016-06-29
EP2663557A1 (en) 2013-11-20
JP2014503557A (ja) 2014-02-13
AU2012205415B2 (en) 2017-02-02
US20130289002A1 (en) 2013-10-31
KR101897952B1 (ko) 2018-09-12
RU2013137750A (ru) 2015-02-20
CA2824516C (en) 2019-02-26
CL2013002025A1 (es) 2013-12-27
CA2824516A1 (en) 2012-07-19
EP2663557B1 (en) 2015-05-27
BR112013017974B1 (pt) 2021-05-25
AU2012205415A1 (en) 2013-08-01
TW201309677A (zh) 2013-03-01
MX339455B (es) 2016-05-27
ZA201305233B (en) 2014-11-26
KR20140037031A (ko) 2014-03-26
IL227406A (en) 2017-02-28
US8969359B2 (en) 2015-03-03
SG191946A1 (en) 2013-08-30
JP6085829B2 (ja) 2017-03-01
RU2609259C2 (ru) 2017-01-31
MX2013008162A (es) 2013-08-27
TWI546298B (zh) 2016-08-21
NZ612961A (en) 2015-10-30
BR112013017974A2 (pt) 2018-05-02
CN103443096A (zh) 2013-12-11
US8481551B2 (en) 2013-07-09
IL227406A0 (en) 2013-09-30
US20120184512A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
AR084863A1 (es) Inhibidores de girasa y topoisomerasa iv utiles para tratar infecciones bacterianas y composiciones farmaceuticas que los contienen
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
IN2014MN02106A (es)
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
MX2014001067A (es) Inhibidores de replicacion del virus de influenza.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
UA111770C2 (uk) Інгібітори бромдомену
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
EA201500544A1 (ru) НОВЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ АГЕНТОВ И ИНГИБИТОРОВ β-ЛАКТАМАЗ
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY32062A (es) Inhibidores de beta-secretasa
AU2012214029A8 (en) Rorgammat inhibitors
BR112015031726A2 (pt) composição para tratamento bucal à prova de manchas
CR20140134A (es) Composiciones farmacéuticas
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
AR093226A1 (es) Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
SG10201900541QA (en) Derivatives of xanthone compounds
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
MX341342B (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.

Legal Events

Date Code Title Description
FG Grant, registration